NASDAQ:HCAT - Health Catalyst Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $50.42
Forecasted Upside: -9.89 %
Number of Analysts: 10
Breakdown:
0 Sell Ratings
0 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$55.95 As of 08/4/2021 01:00 AM ET

▼ -1.46 (-2.54%)

1 month | 3 months | 12 months

Get New Health Catalyst Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for HCAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCAT

^$50.42

▼ -9.89% Downside Potential

This price target is based on 10 analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $50.42, with a high forecast of $66.00 and a low forecast of $37.00. The average price target represents a -9.89% upside from the last price of $55.95.

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Health Catalyst.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/11/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/11/2020

0 strong buy ratings
14 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/9/2020

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/7/2020

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/5/2021

0 strong buy ratings
12 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/6/2021

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/5/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/4/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/30/2021	SVB Leerink	Boost Price Target	Outperform	$59.00 ➝ $62.00	Medium
6/28/2021	Raymond James	Reiterated Rating	Buy	$66.00	Medium
5/7/2021	The Goldman Sachs Group	Boost Price Target	Buy	$54.00 ➝ $60.00	High
5/7/2021	Raymond James	Boost Price Target	Strong-Buy	$56.00 ➝ $63.00	High
5/7/2021	SVB Leerink	Boost Price Target	Outperform	$53.00 ➝ $59.00	High
5/7/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$52.00 ➝ $60.00	High
5/7/2021	Piper Sandler	Boost Price Target	Outperform ➝ Overweight	$54.00 ➝ $57.00	High
4/29/2021	JPMorgan Chase & Co.	Initiated Coverage	Overweight		Medium
2/26/2021	Piper Sandler	Boost Price Target	Overweight	$50.00 ➝ $54.00	Low
2/26/2021	SVB Leerink	Boost Price Target	Outperform	$40.00 ➝ $53.00	High
2/26/2021	Raymond James	Boost Price Target	In-Line ➝ Strong-Buy	$44.00 ➝ $56.00	High
1/7/2021	Canaccord Genuity	Boost Price Target	Focus Stock ➝ Buy	$43.00 ➝ $50.00	High
12/15/2020	Smith Barney Citigroup	Boost Price Target		$40.00 ➝ $49.00	Medium
12/8/2020	Berenberg Bank	Initiated Coverage	Buy	$44.00	High
11/11/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		High
11/11/2020	Canaccord Genuity	Boost Price Target	Buy	$40.00 ➝ $43.00	Low
11/11/2020	Royal Bank of Canada	Boost Price Target	Outperform	$34.00 ➝ $40.00	Medium
11/11/2020	Raymond James	Boost Price Target	Positive ➝ Strong-Buy	$40.00 ➝ $44.00	High
8/18/2020	Guggenheim	Boost Price Target		$33.00 ➝ $37.00	Low
8/12/2020	Truist Financial	Boost Price Target		$36.00 ➝ $43.00	High
8/12/2020	Stifel Nicolaus	Boost Price Target	Buy	$36.00 ➝ $37.00	High
7/14/2020	Citigroup	Initiated Coverage	Buy	$40.00	Medium
7/10/2020	SVB Leerink	Boost Price Target	Outperform	$32.00 ➝ $40.00	High
6/18/2020	Stifel Nicolaus	Initiated Coverage	Buy	$36.00	High
6/4/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$44.00	Medium
5/15/2020	Guggenheim	Initiated Coverage	Buy	$33.00	Low
5/13/2020	SunTrust Banks	Boost Price Target	Buy	$30.00 ➝ $36.00	Medium
5/13/2020	Royal Bank of Canada	Boost Price Target	Outperform	$30.00 ➝ $34.00	High
5/13/2020	Raymond James	Lower Price Target	Strong-Buy	$46.00 ➝ $40.00	High
5/13/2020	SVB Leerink	Boost Price Target	Outperform	$31.00 ➝ $32.00	High
4/22/2020	SunTrust Banks	Lower Price Target	Buy	$35.00 ➝ $30.00	Low
4/20/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$30.00	Low
4/20/2020	Cantor Fitzgerald	Lower Price Target	Positive ➝ Overweight	$47.00 ➝ $44.00	Low
4/13/2020	SVB Leerink	Initiated Coverage	Outperform	$31.00	High
4/2/2020	Canaccord Genuity	Initiated Coverage	Buy	$40.00	Low
3/26/2020	SunTrust Banks	Lower Price Target	Buy	$46.00 ➝ $35.00	Low
12/19/2019	Raymond James	Initiated Coverage	Strong-Buy	$46.00	High
10/29/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$47.00	High
8/19/2019	SVB Leerink	Initiated Coverage	Outperform	$55.00	Medium
8/19/2019	The Goldman Sachs Group	Initiated Coverage	Buy	$49.00	Medium
8/19/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$50.00	High
8/19/2019	Piper Jaffray Companies	Initiated Coverage	Overweight	$47.00	High
8/19/2019	William Blair	Initiated Coverage	Outperform		High
8/19/2019	SunTrust Banks	Initiated Coverage	Buy	$53.00	High
8/19/2019	Evercore ISI	Initiated Coverage	Outperform	$50.00	High

(Data available from 8/5/2016 forward)

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. The company was founded in 2008 and is headquartered in South Jordan, Utah.

Today's Range

Now: $55.95

$55.88

$57.98

50 Day Range

MA: $56.22

$52.85

$58.64

52 Week Range

Now: $55.95

$29.30

$59.50

Volume

253,332 shs

Average Volume

268,147 shs

Market Capitalization

$2.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Health Catalyst?

The following Wall Street research analysts have issued stock ratings on Health Catalyst in the last twelve months: Berenberg Bank, Canaccord Genuity, Cantor Fitzgerald, Guggenheim, JPMorgan Chase & Co., Piper Sandler, Raymond James, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for HCAT.

What is the current price target for Health Catalyst?

12 Wall Street analysts have set twelve-month price targets for Health Catalyst in the last year. Their average twelve-month price target is $50.42, suggesting a possible downside of 12.2%. Raymond James has the highest price target set, predicting HCAT will reach $66.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $37.00 for Health Catalyst in the next year.
View the latest price targets for HCAT.

What is the current consensus analyst rating for Health Catalyst?

Health Catalyst currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCAT will outperform the market and that investors should add to their positions of Health Catalyst.
View the latest ratings for HCAT.

What other companies compete with Health Catalyst?

Other companies that are similar to Health Catalyst include DigitalOcean, Bumble, DoubleVerify, Medallia, Dada Nexus, TripAdvisor, Switch, Chindata Group, Cardlytics, Blend Labs, Magnite, KnowBe4, Rackspace Technology, Sabre and OneConnect Financial Technology.

How do I contact Health Catalyst's investor relations team?

Health Catalyst's physical mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company's listed phone number is 801-708-6800 and its investor relations email address is [email protected] The official website for Health Catalyst is www.healthcatalyst.com.